Dong-A ST announced on December 15 that it has signed an exclusive domestic distribution and sales agreement with Menarini Korea for the atopic dermatitis treatment "Elidel Cream."
The signing ceremony, held at Dong-A ST's headquarters in Dongdaemun-gu, Seoul, was attended by Jaehoon Jung, President of Dong-A ST, Hanjun Bae, President of Menarini Korea, and other officials from both companies.
At the exclusive domestic distribution and sales contract ceremony for Elidel Cream between Dong-A ST and Menarini Korea, Jaehoon Jung, President and CEO of Dong-A ST (right), and Hanjun Bae, CEO of Menarini Korea, are taking a commemorative photo. Dong-A ST
Elidel Cream is a topical calcineurin inhibitor introduced by the global healthcare company Menarini Korea. It is used as a secondary treatment for mild to moderate atopic dermatitis and is suitable for both short-term and intermittent long-term therapy.
According to the Health Insurance Review and Assessment Service, the number of atopic dermatitis patients in Korea reached approximately 1 million last year. The condition continues to affect not only children and adolescents but also adults, underscoring the growing importance of effective and safe treatment options.
Through this partnership, Menarini Korea will be responsible for the import and supply of Elidel Cream in Korea starting January 1 next year. Dong-A ST will handle domestic promotion, marketing, and distribution, as well as sales and business activities targeting medical institutions such as general hospitals and clinics. Both companies plan to leverage their respective expertise to enhance treatment accessibility in the Korean market.
Dong-A ST has accumulated extensive sales and marketing experience and expertise in the dermatology field through products such as the nail fungus treatment "Jublia," the melasma treatment "Melanon Cream," and the antihistamine "Turion." With this agreement, the company aims to further strengthen its dermatology treatment portfolio and enhance its competitiveness in the domestic dermatology market.
Hanjun Bae, President of Menarini Korea, stated, "Menarini Korea is committed to providing reliable treatments to Korean patients in accordance with the quality standards of the global Menarini Group. This partnership is an important strategic step toward fulfilling that responsibility, and we expect that our collaboration with Dong-A ST will further expand the accessibility and value of Elidel Cream."
Jaehoon Jung, President of Dong-A ST, said, "Through this collaboration, we expect to further strengthen Dong-A ST's dermatology treatment portfolio and provide more atopic dermatitis patients with Elidel Cream as a treatment option. Based on our accumulated expertise and experience in the dermatology field, we will do our utmost to expand the market base for Elidel Cream in Korea and enhance its therapeutic value."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
